EUCTR2014-004543-12-Outside-EU/EEA进行中（未招募）不适用
A Phase II, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Fluad® and Fluzone® Influenza Vaccines in Healthy Children Aged 6 to <60 Months.
ovartis Vaccines and Diagnostics Srl.0 个研究点目标入组 350 人开始时间: 2014年11月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Children of 6 to <60 months of age, whose parents/legal guardians have given written informed consent prior to study entry.
- •2. In good health as determined by:
- •a. medical history,
- •b. physical examination,
- •c. clinical judgment of the investigator.
- •3. Able to comply with all study procedures and available for all clinic visits and telephone calls scheduled in the study.
- •4.Informed consent was obtained for all the subjects before enrollment into the study after the nature of the study had been explained.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 360
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any serious disease, such as:
- •b. autoimmune disease (including rheumatoid arthritis),
- •c. diabetes mellitus,
- •d. chronic pulmonary disease,
- •e. acute or progressive hepatic disease,
- •f. acute or progressive renal disease,
- •g. acute or progressive neurological or neuromuscular disease;
- •2. History of any anaphylaxis or serious reaction following administration of vaccine, or hypersensitivity to eggs, egg protein, chicken feathers, influenza viral protein, or any other vaccine component, chemically related substance, or component of the potential packaging materials;
- •3. Known or suspected impairment/alteration of immune function, including:
- •a. immunosuppressive therapy such as systemic corticosteroids known to be associated with the suppression of hypothalamic-pituitary-adrenal (HPA) axis or chronic use of inhaled high-potency corticosteroids within 60 days prior to Visit 1,
- •b. cancer chemotherapy,
- •c. receipt of immunostimulants within 60 days prior to Visit 1,
- •d. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Visit 1 or planned during the full length of the study,
- •e. known HIV infection or HIV-related disease;
- •4. History of Guillain-Barré syndrome;
- •5. Bleeding diathesis;
- •6. Surgery planned during the study period;
- •7. Receipt of another investigational agent within 90 days, or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another clinical study through the end of the study;
- •8. Receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to Visit 1;
- •9. Laboratory-confirmed influenza disease within 6 months prior to Visit 1;
- •10. Ever received two doses of an influenza vaccine before the study, either in two consecutive influenza seasons or in one single influenza season;
- •11. Receipt of an influenza vaccine within 6 months prior to Visit 1;
- •12. Experienced a temperature =38.0°C (=100.4°F ) and/or any acute illness within 3 days prior to Visit 1;
- •13. Any condition, which in the opinion of the Investigator would preclude the subject, on a medical basis, from enrollment or that might interfere with the evaluation of the study objectives.
研究者
相似试验
进行中（未招募）
不适用
Immune Response Induced by a Trivalent Group B strep. vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings.Prophylaxis against Group B Streptococcus infection.EUCTR2010-020840-36-Outside-EU/EEAovartis Vaccines and Diagnostics100
进行中（未招募）
1 期
Testing a vaccine in pregnant woman to protect their newborn babies from blood poisoning caused by a bacteriumInvasive group B streptococcus diseaseMedDRA version: 13.1Level: PTClassification code 10053588Term: Group B streptococcus neonatal sepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-020840-36-BEovartis Vaccines and Diagnostics GmbH100
进行中（未招募）
不适用
A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study toEvaluate the Safety and Immunogenicity of Chiron Meningococcal ACWY ConjugateVaccine in Healthy Children Aged 12-59 MonthsEUCTR2004-001896-21-FIChiron S.r.l.600
进行中（未招募）
不适用
Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years oldHealthy volunteers (immunization against A/California/7/2009 (H1N1)v-like influenza)MedDRA version: 18.0Level: LLTClassification code 10073988Term: Bird fluSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10021433Term: ImmunizationSystem Organ Class: 100000004865EUCTR2011-003512-23-Outside-EU/EEAGlaxoSmithKline Biologicals209
进行中（未招募）
1 期
Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV vaccine (GSK-580299) and Merck's Gardasil® vaccine when administered according to alternative 2-dose schedules in 9-14 years old femalesCervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcinoma) caused by oncogenic human papillomaviruses (HPV).MedDRA version: 14.0Level: LLTClassification code 10033723Term: Papilloma viral infection NOSSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056576Term: Cervical intraepithelial neoplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2011-002035-26-FRGlaxoSmithKline Biologicals1,079